A randomised, comparative study of vonoprazan and esomeprazole 20mg in the treatment of gastric ulcers due to endoscopic submucosal dissection (ESD) for gastric mucosal cancer.

A randomised, comparative study of vonoprazan and esomeprazole 20mg in the treatment of gastric ulcers due to endoscopic submucosal dissection (ESD) for gastric mucosal cancer. - A randomised, comparative study of vonoprazan and esomeprazole 20mg in the treatment of gastric ulcers due to endoscopic submucosal dissection (ESD) for gastric mucosal cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017077

Enrollment

Registered

2015-04-08

Start date

2015-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucosal cancer of the stomach

Interventions

vonoprazan 20 mg esomeprazole 20 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were resected gastric mucosal cancer by ESD.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity of esomeprazole and vonoprzan. 2.Taking medicine which are possible to interact with vonoprazan or esomeprazole. 3.under pregnancy or breast-feeding. 4.Impossibility of oral intake. 5.Past history of resection of upper GI tract.

Design outcomes

Primary

Measure	Time frame
A period to cure post ESD ulcer of the stomach.	—

Countries

Japan

Contacts

Public ContactMotoyoshi Izumi

Machida municipal hospital Department of Gastroenterology

m.izumi@machida-city-hp.jp0427222230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026